

EXHIBIT C2

September FAC									
Drug Name	Date Drug Cosidered by EBD	Use	Current Setup	Recommendation	Navitus Rationale	EBRx Comments	Impacted Members	Cost Details	Accept or Reject
BEYFORTUS INJ	October 2023	RSV	Not Covered	\$0: Standard Vaccine List	The CDC's ACIP reviewed nirsevimab on August 3 and unanimously voted to recommend a single dose of the drug for all infants under 8 months. For children between the ages of 8 and 19 months who are at increased risk of severe RSV disease, CDC recommends a dose in the second season. The WAC cost per injection for both 50 mg/0.5 mL & 100 mg/mL pre-filled syringe is \$495, however children who remain vulnerable through the second RSV season require a 200 mg dose (2 x 100 mg injections). Although this is a new chemical entity, ACIP’s recommendation for use as a vaccine means that we will be adding this product to standard vaccine lists at \$0	Agree with Navitus Rationale	N/A: positive change	WAC: \$495/syringe	
NARCAN NASAL SPRAY (OTC)	October 2023	Opioid overdose reversal	Not Covered	Tier 1	A branded Narcan nasal spray and a generic naloxone nasal spray have received FDA approval for over-the-counter (OTC) use and recently launched. This is an important advancement for public health, so we recommend coverage of these OTC products. Interestingly, the branded Narcan has a lower WAC price of around \$50 per 2-spray package, while the generic OTC naloxone is priced similarly to Rx products at around \$80 per package. As the generic Rx products are currently at the preferred generic tier, we recommend the similarly priced generic OTC be placed at this tier as well. However, branded Rx products are either preferred brand or non-preferred brand, depending on whether they are a Multi-Source N or O. As the OTC branded product is the lowest net cost available, we recommend this also be available at the preferred generic tier.	Agree with Navitus Rationale	N/A: positive change	WAC: \$50 per two spray package	
naloxone hcl nasal spray	October 2023	Opioid overdose reversal	Not Covered	Tier 1	See NARCAN NASAL SPRAY (OTC).	Agree with Navitus Rationale	N/A: positive change	WAC: \$80 per two spray package	
OPVEE NASAL SPRAY	October 2023	Opioid overdose reversal	Not Covered	Tier 2	Nalmefene provides another effective option for treating opioid overdose other than naloxone, with greater μ-opioid receptor affinity and a longer duration of action. Greater receptor affinity and longer duration of action (5.94 hours for nalmefene vs 30-120 minutes for naloxone) may be beneficial for reversal of potent synthetic opioids. Recommendation is to place on preferred brand tier as this product is slightly more expensive than naloxone nasal spray generics (on preferred generic tier), but is not expensive overall, and Navitus encourages access to opioid overdose products.	Agree with Navitus Rationale	N/A: positive change	WAC: \$98 per two count box	

September FAC									
Drug Name	Date Drug Cosidered by EBD	Use	Current Setup	Recommendation	Navitus Rationale	EBRx Comments	Impacted Members	Cost Details	Accept or Reject
desmopressin acetate inj	October 2023	Diabetes insipidus, bleeding associated with hemophilia A + VWD	Tier 1	Not Covered	Pharmacy benefit coverage of desmopressin nasal spray (Stimate equivalent) has been including coverage of injectable desmopressin. We will be updating pharmacy benefit coverage to ensure only the self- administered desmopressin nasal spray is covered. The desmopressin injectable products will be directed to the medical benefit.	2023Q2, EBD had one utilizer of the injectable. Agree with Navitus Rationale	1	WAC: \$51/mL	
DDAVP INJ	October 2023	Diabetes insipidus, bleeding associated with hemophilia A + VWD	Tier 3	Not Covered	See desmopressin acetate inj.	2023Q2: No utilizers. Agree with Navitus Rationale	0	WAC: \$82.51/mL	
INGREZZA PACK 40-80MG	October 2023	Tardive Dyskinesia	Not Covered	Not Covered	Agree with EBRx Rationale	EBRx recommends exclusion of Ingrezza, Austedo, Austedo XR regardless of contracting. These drugs were FDA-approved for Huntington Chorea (we cover tetrabenazine for HC) or for treatment of tardive dyskinesia. There are no head to head trials with any other drugs and was FDA approved because it improved the "AIMS dyskinesia" score. The minimal clinically important difference (MCID) is a score of 2 points different from placebo. Several other drugs have established similar changes in the AIMS dyskinesia scores (including tetrabenazine, which is covered on formulary).	N/A: positive change	WAC: \$286.50 per cap	
INGREZZA CAPSULES	October 2023	Tardive Dyskinesia	Tier 4, PA, QL	Not Covered	See INGREZZA PACK 40-80MG. Of note, added to formulary upon transition to Navitus. Recommended removal as formulary maintenance based on rationale noted above.	See INGREZZA PACK 40-80MG	2	WAC: \$199 - \$267 per cap	
AUSTEDO TABLETS	October 2023	Tardive Dyskinesia	Tier 4, PA, QL	Not Covered	See INGREZZA PACK 40-80MG. Of note, added to formulary upon transition to Navitus. Recommended removal as formulary maintenance based on rationale noted above.	See INGREZZA PACK 40-80MG	1	WAC: \$79 - \$236 per tab	
SYMBICORT INHALER	October 2023	Asthma + COPD	Tier 3	Not Covered	EFFECTIVE 1/1/24: Due to contracting changes, generic version of Symbicort will now be the lowest net cost product available. Symbicort will therefore be removed from formulary and generic budesonide/formoterol will be added in its place.	Agree with Navitus Rationale	45	WAC: \$230.66 - \$390.47 per inhaler	
budesonide/formoterol inhaler	October 2023	Asthma + COPD	Not Covered	Tier 2	See SYMBICORT INHALER.	Agree with Navitus Rationale	N/A: positive change	WAC: \$218.77 - \$250.06/inhaler	

September FAC									
Drug Name	Date Drug Cosidered by EBD	Use	Current Setup	Recommendation	Navitus Rationale	EBRx Comments	Impacted Members	Cost Details	Accept or Reject
ZIEXTENZO INJ	October 2023	Febrile Neutropenia	Tier 4	Not Covered	The manufacturer of Ziextenzo is modifying their distribution strategy as well as eliminating any contracting on the product starting 1/1/24. After evaluating contracting, the new lowest net cost strategy will include retaining Fulphila, which is one of the lowest net cost biosimilars. In addition, Nyvepria, the lowest net cost biosimilar option with new contracting will be added to formulary and replace Ziextenzo, which will no longer be covered.	EBRx comment: no clinical issues with using the lowest net cost pegfilgrastim product. Not sure if this creates issues with our medical benefit rebate contract for Fulphila.	0	WAC: \$6543/injection	
NYVEPRIA INJ	October 2023	Febrile Neutropenia	Not Covered	Tier 4	See ZIEXTENZO INJ.	See Ziextenzo comment	N/A: positive change	WAC: \$6542/injection	
clindamycin vaginal cream	October 2023	Bacterial Vaginosis	Tier 1	Tier 1, QL = 1 tube/fill	Clindamycin vaginal cream is intended to be a single course treatment per guidelines, thus, due to cost being similar to branded agents that are limited to 1 course per fill, we recommend also adding a QL to this product. A majority of claims are for a single tube, so there should not be significant disruption, but the quantity limit will mitigate any potential waste for members trying to fill multiple courses that may go unused.	Agree with Navitus Rationale	22	WAC: \$2.17- \$2.60/gram	
tinidazole tab	October 2023	Bacterial Vaginosis	Tier 3	Tier 1	Due to declining costs (now \$33.29 per claim), we recommend moving tinidazole to the preferred generic tier.	Agree with Navitus Rationale	N/A: positive change	Avg \$33.29 per claim	
CLINDESSE VAGINAL CREAM	October 2023	Bacterial Vaginosis	Tier 3, QL = 1 applicator/fill	Tier 2, QL = 1 applicator/fill	Considering rebates available for Clindesse and Xaciato, making them cost-competitive with generic clindamycin phosphate 2% vaginal cream, recommendation is to move both products to preferred brand and add QL to Xaciato for consistency with other branded products.	Agree with Navitus Rationale based on rebate availability	N/A: positive change	WAC: \$167.02 per course	
XACIATO GEL	October 2023	Bacterial Vaginosis	Not Covered	Tier 2, QL = 1 applicator/fill	See CLINDESSE VAGINAL CREAM.	Agree with Navitus Rationale based on rebate availability	N/A: positive change	WAC: \$180 per course	
THEOPHYLLINE TAB ER, 100mg, 200mg	October 2023	Asthma + COPD	Not Covered	Tier 2	Generic versions of 100 mg and 200 mg theophylline ER 12-hour tablet were launched. While the generic had been previously marketed, the last available product from previous manufacturers expired in 2018. These strengths are being launched at approximately seven times the cost of previously available NDCs, but in-line with pricing for other formulary strengths (300 mg and 450 mg), both of which are currently covered at the preferred brand tier for all formularies. For this reason, coverage of the 100 mg and 200 mg strengths will be mirrored	Agree with Navitus Rationale	N/A: positive change	WAC: \$2.46/tab (100mg), \$2.89/tab (200mg)	
EXKIVITY	October 2023	Locally advanced or Metastatic EGFR Non-Small Cell Lung Cancer	Tier 4	Not Covered	Agree with EBRx Rationale	Exkivity (mobocertinib) will be withdrawn from the market due to lack of benefit in its confirmatory trial. The actual withdrawal date is unknown at this point and drug remains available for purchase.	0	WAC: \$325,458.34 per year	